Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development.
Immunitrack, a leading provider of best-in-class FcRn reagents, is founded on world-class research on MHC-epitope binding. Our proprietary epitope screening platform NeoScreen® measures the affinity and stability of MHC/epitope interactions, with the capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within autoimmunity, immuno-oncology, vaccine production, T cell therapy, and immune monitoring.
Immunitrack’s mission is to provide the pharmaceutical industry and research community with technology and reagents to select therapeutic targets and design novel biotherapeutics at early stages of R&D as well to monitor the effects of lead drug candidates on patient immune responses.
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system.
Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end-users the necessary freedom to operate.